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Methods
Cloning, expression and purification of RT
from patient samples
kobs =
Kpol[dNTP]
Kd.dNTP
+ dNTP
HIV types, groups and subtypes and worldwide distribution
Acknowledgments
HIV -1C comprises 
more than 50% of the 
world’s HIV cases.
Conclusions
More HIV-nonB patients failed therapy 
(25%) than HIV-1B (9%)
NVP & RPV binding affinity varies among 
subtypes indicating its different efficacy 
in different HIV subtypes
Both clinical and biochemical experiment  
results suggest that NNRTIs has different 
susceptibility for different HIV-1 subtypes
Data suggest that NVP can be used for 
02_AG infections efficiently
Data suggest that RPV is not a good anti-
HIV drug for subtype C infections
Data suggest that EFdA can be used for 
all subtypes as a potent anti-HIV drug
NIH/NIGMS P50 GM103368.
Results
Kinetics of NNRTI (RPV) binding 
1. Run dNTP incorporation reactions in a rapid
quench flow machine under single turnover
conditions in presence of increasing
concentration of RPV.
2. Analyze the products on a 20% urea gel.
Plot the amount of product at different RPV
concentrations.
3. Determine amplitude using a burst
equation.
4. Plot amplitude with increasing RPV
concentrations.
5. Fit the data points to obtain RPV binding
affinity (Kd.RPV)
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1. Run dNTP incorporation reactions in a
rapid quench flow machine under
single turnover conditions.
2. Analyze the products on a 20% urea
gel. Plot the amount of product at
different dNTP concentrations.
3. Determine observed rate constants
(kobs) using a burst equation.
4. Plot the observed rates against
increasing dNTP concentrations.
5. Fit the data points to obtain the
optimal polymerization rate (kpol) and
dNTP binding affinity (Kd.dNTP)
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DNA/DNA Template/Primer used in this study Sequence (31/18mer)
3’- CAG TGA CAA GCT CGT GGT TAC GAT AGA TAC C-5’ Template 31
5’- GTC ACT GTT CGA GCA CCA -3’ Primer 18                
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HIV-1C RT is ~ 2-fold less efficient than other subtype 
RTs 
Kinetic parameters of HIV-1C RT on hetero-
polymeric (31/18-mer) DNA/DNA template-primer 
HIV-1C RT
Enzyme
HIV-1B RT
Kd.NVP (nM)
01_AE RT 78.1 ± 7 
02_AG RT
NVP binding affinity (Kd.NVP) to HIV-1B and HIV-
non B RTs
Nevirapine binding affinity varies among different 
subtypes
02_AG appears more susceptible to NVP
101.1 ± 32
100.7± 17
21.2 ± 1 
RPV binding affinity (Kd.RPV) to HIV-1B and HIV-
non B RTs
HIV-1C RT
Enzyme
HIV-1B RT
Kd.RPV (nM)
21 ± 2
66 ± 7
01_AE RT 31 ± 4
02_AG RT 21 ± 3
Rilpivirine binding affinity varies among different 
subtypes
HIV-1 Subtype C appears less susceptible to RPV
Enzyme Kd.dATP (μM) kpol (s-1) efficiency 
(μM-1s-1)
HIV-1B RT 3.4 12.5 3.7
HIV-1C RT 14.54 26.69 1.8
01_AE RT 2.0 10.8 5.4
02_AG RT 2.1 10.38 4.9
Alternative approach
Adenosine analog RT inhibitor has been 
designed by our lab and collaborators 
Do HIV-nonB patients fail RPV easier than HIV-1B?
Therapy outcome of 117 patient Swedish InfCare Cohort
Nevirapine (NVP) is a first-generation non-nucleoside reverse 
transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-
1). However, with the emergence of resistance mutations due to a low genetic 
barrier under NVP pressure, new (second generation) NNRTIs have been 
approved. Rilpivirine (RPV), a second generation NNRTI, is not frequently 
used in low- and middle- income countries (LMICs) that bear the major HIV 
burden. RPV has been co-formulated with tenofovir (TDF) and emtricitabine 
(FTC) and has been recommended for patients with viral loads <100,000 
copies/mL, inhibiting viruses that are resistant to NVP. It is now being 
considered in many LMICs.
To understand RPV efficacy in HIV-1 subtypes prevalent in LMICs, we 
cloned RT genes from patients infected with four different HIV-1 subtypes: 
subtype B (HIV-1B), subtype C (HIV-1C), and recombinant forms CRF01_AE 
and CRF02_AG. HIV-1B is most prevalent in western countries and accounts 
for only ~12% of all infections. However, HIV-1C, which accounts for ~52% of 
all HIV infections, is most prevalent in LMICs. In vitro inhibition assays were 
performed with the four patient-derived RTs.
Our results show that overall, NVP binds RTs with lower affinity than 
RPV, suggesting that NVP has lower effectiveness than RPV. However, NVP 
binds 02_AG RT with better affinity than RPV. Hence, NVP may still be 
effective for patients infected with 02_AG. Furthermore, RPV binding affinity 
with HIV-1C is lower than other subtypes. This result is consistent with clinical 
results, showing less efficacy of RPV among HIV-1C infected patients.
HIV-1C RT
Enzyme
HIV-1B RT
Kd.EFdA(μM)
0.17
01_AE RT 0.95
02_AG RT 0.20
EFdA binding affinity (Kd.EFdA) to HIV-1B 
and HIV-non B RTs
EFdA binds most of subtypes efficiently
0.23
